Duchenne Muscular Dystrophy
Conditions
Keywords
DMD, Myopathy, Natural History, Muscular dystrophy, Biomarkers, Muscle testing
Brief summary
To characterize the natural history and progression of Duchenne Muscular Dystrophy (DMD) to help inform the design of future studies, to capture biomarkers of safety and disease progression and to provide comparative data for the development of rare exons for which formal controlled trials are not feasible.
Detailed description
This is a prospective study. All DMD patients that fulfil the inclusion/exclusion criteria are eligible although the study is weighted towards ambulant subjects aged 3 years or older. There will be 7 study visits and subjects will be in the study for a maximum of 3 years. Visits will occur every 6 months (+/- 1 month). Up to 250 DMD subjects planned in the following categories : * 75 % ambulant subjects aged between 3 and 18 years at study entry * 25% non-ambulant subjects with a maximum age of 18 years at study entry Subjects will be asked to perform muscle testing assessment with a clinical evaluator, such as walking for 6 minutes, climb stairs, breathe in a tube, see how they can move their arms and legs. They will be asked questions about how they feel overall and perform daily activities. These measurements will be assessed every 6 months. Urine and blood samples will be collected once a year to measure biomarkers that will allow to have a better overview of DMD.
Interventions
OTHERObservational study
There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
Sponsors
BioMarin Pharmaceutical
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
3 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of DMD resulting from a mutation in the DMD gene confirmed by a state of the art DNA diagnostic technique covering all DMD gene exons. * Age 3 - 18 years * Willing and able to comply with protocol requirements * Life expectancy of at least 3 years * Able to give informed assent and/or consent in writing signed by the subject and/or parent(s)/legal guardian (according to local regulations)
Exclusion criteria
* Current participation in a clinical study with an Investigational Medicinal Product (IMP) * Participation within the previous 1 month in a clinical study with an IMP
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 6 minute walk distance | Change from visit 1 walking distance | Participants are asked to walk at their own preferred speed on a fixed distance for 6 minutes. Subjects are warned of the time and that they may stop earlier if they feel unable to continue. Total distance walked within 6 minutes (or until stopping) is recorded. |
Countries
Argentina, Belgium, Brazil, France, Germany, Italy, Netherlands, Sweden, Turkey (Türkiye), United States
Outcome results
None listed